We are developing a portfolio of novel therapeutics targeting metabolic diseases. Substantial unmet needs persist in obesity, particularly in achieving sustained weight loss, as well as addressing the key underlying pathologies that impact cardiometabolic health outcomes. Alveus aims to address these critical issues, delivering meaningful improvements in patient outcomes. In addition to our lead program, we are advancing an amylin pipeline of highly differentiated small molecules, peptides, and novel formats across multiple indications.
Human genetic studies and functional mapping highlight the incretin axis as a key regulator of metabolic health. Loss-of-function variants in GIPR are associated with lower BMI and improved cardiometabolic traits, and GLP-1 receptor agonists are proven to deliver clinically validated benefits in metabolic diseases.
Competitive in vitro potency and weight loss with lean mass preservation in obese NHPs. Weight loss and weight maintenance demonstrated in Ph1 clinical trial.
GIPR antagonism enhances the weight loss effects of GLP-1R agonism and may allow for infrequent dosing.
Novel recombinant humanized GIPR antagonist IgG-4 antibody – GLP1 agonist peptide fusion protein.